Literature DB >> 6749179

Biosynthesis of a putative protective Plasmodium knowlesi merozoite antigen.

J A Deans, A W Thomas, T Alderson, S Cohen.   

Abstract

A putative protective Plasmodium knowlesi antigen, recognized by two monoclonal antibodies which prevent invasion of erythrocytes by merozoites in vitro, is synthesised only by schizonts with 7 or more nuclei, during the last 1.5-2 h of the 24 h erythrocytic cycle of parasite development. The 66 000 MW antigen, which constitutes a minor parasite protein, is processed at the time of schizont rupture and merozoite release, to give rise to two smaller molecules of 44 000 and 42 000 MW. The 44 000 and 42 000 MW antigens and traces of the 66 000 MW antigen are present on the surface of isolated merozoites and the smaller antigens are readily shed. The antigens which are shed are soluble in culture medium and are not readily degraded further. None of the molecules can be detected in newly invaded ring stage parasites, indicating that they are either excluded when the merozoite invades, or if internalised, they rapidly undergo further structural alteration since newly parasitised red cells no longer contain epitopes which react with the inhibitory monoclonal antibodies. This antigen is distinct from other putative protective antigens described in bloodstage malaria parasites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6749179     DOI: 10.1016/0166-6851(84)90065-3

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  8 in total

1.  Structural characterization of apical membrane antigen 1 (AMA1) from Toxoplasma gondii.

Authors:  Joanna Crawford; Michelle L Tonkin; Ognjen Grujic; Martin J Boulanger
Journal:  J Biol Chem       Date:  2010-03-19       Impact factor: 5.157

2.  Toxoplasma gondii homologue of plasmodium apical membrane antigen 1 is involved in invasion of host cells.

Authors:  A B Hehl; C Lekutis; M E Grigg; P J Bradley; J F Dubremetz; E Ortega-Barria; J C Boothroyd
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

3.  Functional analysis of Plasmodium falciparum merozoite antigens: implications for erythrocyte invasion and vaccine development.

Authors:  Alan F Cowman; Deborah L Baldi; Manoj Duraisingh; Julie Healer; Kerry E Mills; Rebecca A O'Donnell; Jennifer Thompson; Tony Triglia; Mark E Wickham; Brendan S Crabb
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-01-29       Impact factor: 6.237

4.  Apical membrane antigen 1, a major malaria vaccine candidate, mediates the close attachment of invasive merozoites to host red blood cells.

Authors:  G H Mitchell; A W Thomas; G Margos; A R Dluzewski; L H Bannister
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Structure and development of the surface coat of erythrocytic merozoites of Plasmodium knowlesi.

Authors:  L H Bannister; G H Mitchell; G A Butcher; E D Dennis; S Cohen
Journal:  Cell Tissue Res       Date:  1986       Impact factor: 5.249

6.  Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT™ protects against blood-stage challenge in rhesus macaques.

Authors:  Muzamil Mahdi Abdel Hamid; Edmond J Remarque; Leonie M van Duivenvoorde; Nicole van der Werff; Vanessa Walraven; Bart W Faber; Clemens H M Kocken; Alan W Thomas
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

Review 7.  Progress with viral vectored malaria vaccines: A multi-stage approach involving "unnatural immunity".

Authors:  Katie J Ewer; Kailan Sierra-Davidson; Ahmed M Salman; Joseph J Illingworth; Simon J Draper; Sumi Biswas; Adrian V S Hill
Journal:  Vaccine       Date:  2015-10-21       Impact factor: 3.641

8.  Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.

Authors:  D L Narum; S A Ogun; A W Thomas; A A Holder
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.